Compartir
Biomaterial-Assisted 3D In Vitro Tumor Models: From Organoid towards Cancer Tissue Engineering Approaches (en Inglés)
Danti, Serena ; Negrini, Nicola Contessi ; Franchi, Alessandro (Autor)
·
Mdpi AG
· Tapa Dura
Biomaterial-Assisted 3D In Vitro Tumor Models: From Organoid towards Cancer Tissue Engineering Approaches (en Inglés) - Danti, Serena ; Negrini, Nicola Contessi ; Franchi, Alessandro
$ 90.250
$ 164.090
Ahorras: $ 73.840
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Miércoles 19 de Junio y el
Lunes 01 de Julio.
Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Biomaterial-Assisted 3D In Vitro Tumor Models: From Organoid towards Cancer Tissue Engineering Approaches (en Inglés)"
This reprint focuses on fundamental and applied research involving the combination of biomaterials and cancer cells to develop a three-dimensional (3D) tumor microenvironment in vitro, in which carcinogenesis mechanisms can be studied and therapies can be screened. Such models are becoming quite popular within the bioengineering community; thus, many technologies are being tested to obtain the best scaffold for each tumor. In any case, only a tight interaction of bioengineers with cancer biologists and oncologists can make such 3D models progress, with them finally reaching a clinical relevance. On the other hand, the medical community is approaching simpler 3D in vitro models not provided with sufficient extracellular matrix biomimicry, such as spheroids and organoids, which may not be self-exhaustive; therefore, cancer researchers could benefit from closer contact with bioengineers. The aim of this reprint is to help generate shared knowledge and promote strong interdisciplinary collaboration with the ultimate goal of contributing to the acceleration of the discovery and validation of more precise therapies to fight cancer.
